New combo therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT04109729
First seen Nov 21, 2025 · Last updated Jun 14, 2026 · Updated 21 times
Summary
This early-phase study tested a combination of two drugs—nivolumab (an immunotherapy) and Radium-223 (a radioactive drug)—in 39 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goals were to check safety and see if the treatment could reduce tumor DNA in the blood. Participants received both drugs over several weeks, and researchers monitored side effects and signs of cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.